Mathematical approach to understand the kinetics of α-synuclein aggregation: Relevance to Parkinson's disease

Computers in Biology and Medicine

Volumn 38, Issue 10, 2008, Pages 1084-1093

  Bharathi, P ^a   Nagabhushan, P ^b   Rao, K S J ^a  

^a CENTRAL FOOD TECHNOLOGICAL RESEARCH INSTITUTE   (India)

^b UNIVERSITY OF MYSORE   (India)

Author keywords

Synuclein; Absolute analysis; Binding efficiency; Elongation; Fibrillogenesis; Mathematical; Metals; Nucleation; Self analysis

Indexed keywords

AGGLOMERATION; CHEMOTHERAPY; COPPER; DRUG DELIVERY; DRUG DOSAGE; EPITAXIAL GROWTH; HEALTH; METAL IONS; METALS; MONOMERS; REDOX REACTIONS;

ABSOLUTE-ANALYSIS; BINDING EFFICIENCY; CLINICAL APPLICATIONS; COPPER (CU); ELONGATION; FIBRILLOGENESIS; FLUORESCENCE STUDIES; MATHEMATICAL; MATHEMATICAL APPROACHES; MATHEMATICAL SIMULATIONS; NEURODEGENERATION; NUCLEATION; PARKINSON'S DISEASE; REDOX ACTIVE METAL IONS; SELF-ANALYSIS; SYNUCLEIN; SYNUCLEIN AGGREGATION;

MATHEMATICAL MODELS;

ALPHA SYNUCLEIN; COPPER; IRON; METAL ION;

ARTICLE; FLUORESCENCE ANALYSIS; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; NERVE DEGENERATION; OXIDATION REDUCTION REACTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; SIMULATION;

ALPHA-SYNUCLEIN; HUMANS; KINETICS; MICROSCOPY, ELECTRON, TRANSMISSION; PARKINSON DISEASE; SPECTROMETRY, FLUORESCENCE;

EID: 53049108584     PISSN: 00104825     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.compbiomed.2008.08.008     Document Type: Article

References (44)

1. Goedert M. α-Synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2 (2001) 492-501
2. Spillantini M.G., Schimdt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. α-Synuclein in lewy bodies. Nature 388 (1997) 839-840
3. Baba M., Nakajo S., Tu P.H., Tomita T., Nakaya K., and Lee V.M. Aggregation of α-synuclein in lewy bodies of sporadic Parkinson's disease and dementia with lewy bodies. Am. J. Pathol. 152 (1998) 879-884
4. Wakabayashi K., Yoshimoto M., Tsuji S., and Takahashi H. Alpha synuclein immuno-reactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci. Lett. 249 (1998) 180-182
5. Tanner C.M. The role of environmental toxins in the etiology of Parkinson's disease. Trends Neurosci. 12 (1989) 49-54
6. Hirsch E.C., Brandel J.P., Galle P., Javoy-Agid F., and Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem. 56 (1991) 446-451
7. Good P.F., Olanow C.W., and Perl D.P. Neuromelanin-containing neurons of the substantia nigra accumulates iron and aluminium in Parkinson's disease: a LAMMA study. Brain Res. 593 (1992) 343-346
8. Yasui M., Kihira T., and Ota K. Calcium, magnesium aluminium concentrations in Parkinson's disease. Neurotoxicology 13 (1992) 593-600
9. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., Kortsha G.X., Brown G.G., and Richardson R.J. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 20 (1999) 239-247
10. Altschuler E. Aluminum containing antacids as a cause of idiopathic Parkinson's disease. Med. Hypotheses 53 (1999) 22-23
11. De Le Couteur D.G., McLean A.J., Taylor M.C., Woodham B.L., and Board P.G. Pesticides and Parkinson's disease. Biomed. Pharmacother. 53 (1999) 122-130
12. Dexter D.T., Wells F.R., Lees A.J., Agid F.J., Agid Y., Jenner P., and Marsden C.D. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52 (1989) 1830-1836
13. Dexter D.T., Carayon A., Agid F.J., Agid Y., Wells F.R., Daniel S.E., Lees A.J., Jenner P., and Marsden C.D. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114 (1991) 1953-1975
14. Riederer P., Sofic E., Rausch W.D., Schimidt B., Reynolds G.P., Jellinger K., and Youdim M.B. Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brains. J. Neurochem. 52 (1989) 515-520
15. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., and Goedert M. α-Synuclein in filamentous inclusions of lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Nat. Acad. Sci. (USA) 95 (1998) 6469-6473
16. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
17. Kruger R., Kuhn W., Muller T., Woitalla D., Graeder M., and Kosel S. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nature Genet. 18 (1998) 106-108
18. Greenbaum E.A., Graves C.L., Mishizen-Eberz A.J., Lupoli M.A., Lynch D.R., Englander S.W., Axelsen P.H., and Giasson B.I. The E46K mutation in alpha-synuclein increases amyloid fibril formation. J. Biol. Chem. 280 (2005) 7800-7807
19. Pandey N., Schmidt R.E., and Galvin J.E. The alpha-synuclein mutation E46K promotes aggregation in cultured cells. Exp. Neurol. 197 (2006) 515-520
20. Choi W., Zibaee S., Jakes R., Serpell L.C., Davletov B., Crowther R.A., and Goedert M. Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett. 576 (2004) 363-368
21. Maroteaux L., Campanelli J.T., and Scheller R.H. Synuclein: a neuron specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8 (1998) 2804-2815
22. Jakes R., Spillantini M.G., and Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 345 (1994) 27-32
23. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H.A., Kittel A., and Saitoh T. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14 (1995) 467-475
24. George J.M., Jin H., Woods W.S., and Clayton D.F. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15 (1995) 361-372
25. Uversky V.N. Natively unfolded proteins: a point where biology waits where biology waits for physics. Protein Sci. 11 (2002) 739-756
26. Naiki H., Higuchi K., Matsushima K., Shimada A., Chen W.H., Hosokawa M., and Takeda T. Fluorometric examination of tissue amyloid fibrils in murine senile amyloidosis: use of the fluorescent indicator, thioflavine T. Lab Invest. 62 (1990) 768-773
27. Uversky V.N., Li J., and Fink A.L. Metal-triggered structural transformation, aggregation and fibrillation of human α-synuclein, a possible molecular link between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 276 (2001) 44284-44296
28. Wood S.J., Wypych J., Steavenson S., Louis J.C., Citron M., and Biere A.L. Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274 (1999) 19509-19512
29. Jarrett J.T., and Lansbury Jr. P.T. Amyloid fibril formation requires a chemically discriminating nucleation event: studies of an amyloidogenic sequence from the bacterial protein. OsmB. Biochem. 31 (1992) 12345-12352
30. Jarrett J.T., and Lansbury Jr. P.T. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?. Cell 73 (1993) 1035-1058
31. Lomakin A., Chung D.S., Benedek G.B., Kirschner D.A., and Teplow D.B. On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantitation of rate constants. Proc. Nat. Acad. Sci. (USA) 93 (1996) 1125-1129
32. Murphy R.M., and Pallitto M.M. Probing the kinetics of beta-amyloid self-association. J. Struct. Biol. 130 (2000) 109-122
33. Murphy R.M., and Pallitto M.M. A mathematical model of the kinetics of beta-amyloid fibril growth from the denatured state. Biophys. J. 81 (2001) 1805-1822
34. Weinreb P.H., Zhen W., Poon A.W., Conway K.A., and Lansbury P.T. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35 (1996) 13709-13715
35. McLean P.J., Kawamata H., Ribich S., and Hyman B.T. Membrane association and protein conformation of α-synuclein in intact neurons, effect of Parkinson's disease-linked mutations. J. Biol. Chem. 275 (2000) 8812-8816
36. Gomez-Tortosa E., Gonzalo I., Newell K., Garcia Y.J., Vonsattel P., and Hyman B.T. Patterns of protein nitration in dementia with lewy bodies and striato-nigral degeneration. Acta Neuropathol. (Berlin) 103 (2002) 495-500
37. Uversky V.N., Li J., and Fink A.L. Evidence for a partially folded intermediate in α-synuclein fibril formation. J. Biol. Chem. 276 (2001) 10737-10744
38. Paik S.R., Lee J.H., Kim D.H., Chang C.S., and Kim J. Aluminium induced structural alterations of the precursor of the non-Aβ component of Alzheimer disease amyloid. Arch. Biochem. Biophys. 344 (1997) 325-334
39. Paik S.R., Shin H.J., Lee J.H., Chang C.S., and Kim J. Copper (II)-induced self-oligomerisation of α-synuclein. Biochem. J. 340 (1999) 821-828
40. Bharathi, and Rao K.S.J. Thermodynamics imprinting reveals differential binding of metals to α-synuclein: relevance to Parkinson's disease. Biochem. Biophys. Res. Commun. 359 1 (2007) 115-120
41. Bharathi, Indi S.S., and Rao K.S.J. Copper and Iron induced differential morphology of fibrils in α-synuclein: TEM study. Neurosci. Lett. 424 2 (2007) 78-82
42. Tomski S.J., and Murphy R.M. Kinetics of aggregation of synthetic beta-amyloid peptide. Arch. Biochem. Biophys. 294 (1992) 630-638
43. Naiki H., and Nakakuki H. First-order kinetic model of Alzheimer's beta-amyloid fibril extension in vitro. Lab Invest. 74 (1998) 374-383
44. Lomakin A., Teplow D.B., Kirschner D.A., and Benedek G.B. Monitoring protein assembly using quasielastic light scattering spectroscopy. Methods Enzymol. 309 (1999) 429-459